the present study aims to evaluate the possible anti-fibrotic effect of calci-potriol, cholecalciferol, aliskiren, eprosartan and ramipril on carbon tetra-chloride (CCl4) induced liver fibrosis in rats. Methods: Fifty six Spague Dawely rats were randomly allocated into seven groups. All rats were ex-posed to induction of hepatic fibrosis by intraperitoneal (ip) injection of CCl4 twice/week for 8 successive weeks except control healthy group. The rats were treated with either calcipotriol (20 ug/Kg), Cholecalciferol (500 IU/kg), aliskiren (10mg/kg), eprosartan (60mg/kg) and ramipril (10mg/kg) simulta-neously with CCl4 treatment. Results: all the tested drugs have significant improvement in liver function tests (liver enzymes, bilirubin and albumin), oxidative stress markers (reduced glutathione, malondialdehyde and nitric oxide), transforming growth factor-b1 (TGF-b1) and fibrotic score. Only cal-cipotriol and cholecalciferol are significantly decrease renin gene expres-sion in liver and kidney tissues while cholecalciferol alone has significant in-crease in serum calcium and 25 hydroxy vitamin D [25(OH)D] levels. Conclusion: these results suggest that calcipotriol, cholecalciferol, aliskiren, eprosartan and ramipril have antifibrotic effect. Vitamin D receptor (VDR) agonists (Calcipotriol and cholecalciferol) inhibit renin gene expression and have better antifibrotic effect than renin angiotensin blockers (aliskiren, ep-rosartan and ramipril). Eprosartan has better antifibrotic effect than aliskiren and ramipri